

Preclinical evaluation of the peptide candidate CBT-001-2334 for the development of CAIX-targeted radiopharmaceuticals for tumor diagnosis and therapy



ONCOLOGY

Preclinical

Product Type	RPT
Indication	Solid tumor
Target	Carbonic anhydrase IX
MoA(Mechanism of Action)	Our CAIX-targeting peptide selectively binds to overexpressed markers on cancer cells, ensuring high-precision accumulation of radioisotopes. This dual-action approach enables real-time SPECT/PET imaging for accurate diagnosis, while the isotope's radioactive decay induces targeted tumor destruction with minimal off-target effects.
Competitiveness	CBT-001-2334 is a next-generation radiopharmaceutical optimized for CAIX-positive tumors. It surpasses global clinical-stage competitors like ITM-91 in both binding affinity and pharmacological efficacy. • Superior Efficacy: Outperforms ITM-91 in head-to-head potency and tumor suppression. • Precision Targeting: High CAIX selectivity with optimal physicochemical stability. • Market Advantage: A validated lead candidate with clear technological superiority in the global theranostics landscape.
Development Stage	Preclinical
Route of Administration	Parenteral -Intravenous

Any unauthorized distribution or reproduction of this material is strictly prohibited.